Dendreon to Host Conference Call on May 9 to Announce First Quarter
-- Company Announces Webcast Presentations at Upcoming Conferences --
Bank of America Merrill Lynch 2013 Health Care Conference
SEATTLE -- April 24, 2013
April 24, 2013--Dendreon Corporation (Nasdaq: DNDN) today announced that
management will host a conference call on Thursday, May 9, 2013, at 9:00 a.m.
EDT to review first quarter financial results.
Access to the discussion may be obtained as follows:
Time: 9:00 a.m. EDT / 6:00 a.m. PDT
Date: May 9, 2013
Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international);
conference pass code: 53497612
Webcast: www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to
participate in the live conference call by dialing 1-800-585-8367 or
+1-404-537-3406 for international callers; the conference ID number is
53497612. The replay will be available from 12:00 p.m. EDT on Thursday, May 9,
until 11:59 p.m. EDT on Monday, May 15. In addition, the webcast will be
archived for on-demand listening for 90 days at www.dendreon.com.
Dendreon Corporation also announced that management will present at the
*Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas,
NV, on May 14 at 1:40 p.m. PDT
*Deutsche Bank Securities 38th Annual dbAccess Health Care Conference in
Boston, MA, on May 30, 2012, at 10:40 a.m. EDT
The presentations will be audio webcast live and available for replay from
Dendreon's website, www.dendreon.com. If you are unable to listen to the live
webcasts, they will be archived on the site following the presentation. To
access the replays, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon's first
product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug
Administration (FDA) in April 2010. Dendreon is exploring the application of
additional ACI product candidates and small molecules for the potential
treatment of a variety of cancers. The Company is headquartered in Seattle,
Washington and is traded on the NASDAQ Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
Lindsay Rocco, 862-596-1304
Nicole Soley, 206-455-2220
Press spacebar to pause and continue. Press esc to stop.